Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.97 [0.89, 1.07]Studies not reportedLow